miR-505-5p and miR-193b-3p: potential biomarkers of imatinib response in patients with chronic myeloid leukemia

Leuk Lymphoma. 2017 Aug;58(8):1981-1984. doi: 10.1080/10428194.2016.1272681. Epub 2017 Jan 16.

Authors

Suganthi S Ramachandran¹, Pamchui Muiwo², Hafiz M Ahmad³, Ravindra Mohan Pandey⁴, Surender Singh¹, Sameer Bakhshi⁵, Lalit Kumar⁵, Alok Bhattacharya², Yogendra Kumar Gupta¹

Affiliations

¹ a Department of Pharmacology , All India Institute of Medical Sciences , New Delhi , India.
² b School of Life Sciences, Jawaharlal Nehru University , New Delhi , India.
³ c Department of Cancer Cell and Molecular Biology , University of Massachusetts Medical School , Worcester , MA , USA.
⁴ d Department of Biostatistics , All India Institute of Medical Sciences , New Delhi , India.
⁵ e Department of Medical Oncology , Dr. BRA IRCH, All India Institute of Medical Sciences , New Delhi , India.

PMID: 28093001
DOI: 10.1080/10428194.2016.1272681

No abstract available

Publication types

Letter

MeSH terms

Adolescent
Adult
Antineoplastic Agents / administration & dosage
Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use*
Biomarkers, Tumor*
Child
Drug Resistance, Neoplasm / genetics
Female
Gene Expression Profiling
Gene Expression Regulation, Leukemic
Humans
Imatinib Mesylate / administration & dosage
Imatinib Mesylate / adverse effects
Imatinib Mesylate / therapeutic use*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / mortality
Male
MicroRNAs / genetics*
Middle Aged
Protein Kinase Inhibitors / administration & dosage
Protein Kinase Inhibitors / adverse effects
Protein Kinase Inhibitors / therapeutic use*
Treatment Outcome
Young Adult

Substances

Antineoplastic Agents
Biomarkers, Tumor
MIRN193 microRNA, human
MIRN505 microRNA, human
MicroRNAs
Protein Kinase Inhibitors
Imatinib Mesylate